Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-630: Adjuvant Pembrolizumab After Surgery and Radiation in High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma
2022-500395-57-00Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 24
01
Overview
Phase 3, randomised, double-blind trial in cutaneous squamous cell carcinoma (cSCC) comparing Pembrolizumab arm with Placebo arm (2 arms). Primary endpoint: Recurrence-Free Survival (RFS) as Assessed by the Investigator and Confirmed by Biopsy. Started Jan 2023; status: completed.
02
Drugs
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on 2022-500395-57-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500395-57-00.